`
`
`
`
`
`
`
`Copyright 1990 PR Newswire Association, Inc.
`PR Newswire
`
`November 8, 1990, Thursday
`
`
`SECTION: Washington Dateline
`
`DISTRIBUTION: TO NATIONAL AND MEDICAL EDITORS
`
`LENGTH: 327 words
`
`HEADLINE: FDA ISSUES GHB WARNING
`
`DATELINE: WASHINGTON, Nov. 8
`
`BODY:
`
` The Food and Drug Administration today warned consumers to discontinue use of
`an illegally marketed drug -- GHB or gamma hydroxybutyric acid -- that has been promoted
`as a "legal psychedelic" but has caused more than 30 people in California, Florida
`and Georgia to become ill with symptoms ranging from nausea and vomiting to severe
`respiratory problems, seizures and coma.
`
`Health departments in those states have been working with the FDA to learn more
`about the GHB-linked illnesses. Thus far, the investigation has uncovered strong
`evidence linking GHB consumption to the illnesses.
`
`Gamma hydroxybutyric acid, also called sodium oxybate and gamma hydroxybutyrate
`sodium, is a chemical that is being promoted for strength training, body building,
`weight loss and as a replacement for L-tryptophan, a food supplement that FDA ordered
`removed from the market last year after it was linked to a rare blood disorder.
`
`GHB has been used in Europe as an anesthetic adjunct and it is being evaluated
`in FDA-approved clinical trials for the treatment of narcolepsy.
`
`The FDA offered consumers the following medical advice:
`
`-- Anyone taking GHB outside of physician-supervised clinical trials should stop
`immediately.
`
`-- Anyone who has consumed GHB and is experiencing seizures, uncontrolled shaking,
`headache, unexplained drowsiness or other central nervous system disorders, nausea,
`vomiting or diarrhea should consult their physician immediately.
`
`-- Physicians treating patients exhibiting these conditions should report these
`cases to their local poison control center.
`
`According to the California health department, GHB is sold through mail order outlets,
`health food stores, body building gyms and fitness centers. It is marketed as powder
`or granules. CONTACT: Bill Grigg, 301-443-3285 or, after hours, 202-652-1864; or Donald
`McLearn, 301-443-4177 or, after hours, 301-926-6909, both of the Food and Drug
`Administration
`
`LOAD-DATE: 110890 DC020
`
`JAZZ EXHIBIT 2001
`Par Pharm., Inc. et al. (Petitioners) v. Jazz Pharms., Inc. (Patent Owner)
`Case CBM2014-00151
`
`Page 1 of 1
`
`